Figure S1. Immunohistochemical analysis of samples derived from patients with breast cancer. The presentations of breast tumor tissues from patients with a (A) Ki-67 level <30%, a (B) Ki-67 level  $\ge30\%$ , (C) IHC++ and (D) IHC+++. IHC, immunohistochemistry.




Figure S2. Comparison of tpCR between neoadjuvant pyrotinib plus trastuzumab and chemotherapy vs. pyrotinib plus chemotherapy. tpCR, total pathological complete response.

